Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. FIS
7. CVS
8. SPY
9. SWKS
10. XYZ

Go back to Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 7c

Conatus Pharmaceuticals Reports 2015 Financial Results and Program Updates

March 9, 2016 4:05 PM EST

SAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31, 2015, and provided updates on its clinical development programs.

Financial ResultsThe net loss for the fourth quarter of 2015 was $6.0 million compared with $5.3 million for the fourth quarter of 2014. The net loss for the full year 2015 was $24.1 million compared with $22.3 million for the full year 2014.

Research and development expenses... More